Connection
Jeffrey Goldstein to Polymorphism, Genetic
This is a "connection" page, showing publications Jeffrey Goldstein has written about Polymorphism, Genetic.
|
|
Connection Strength |
|
|
|
|
|
0.612 |
|
|
|
-
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997 Feb; 7(1):59-64.
Score: 0.142
-
Faletto MB, Linko P, Goldstein JA. A single amino acid mutation (Ser180----Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. J Biol Chem. 1992 Jan 25; 267(3):2032-7.
Score: 0.100
-
Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009 Jul-Aug; 43(1):119-28.
Score: 0.082
-
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb; 83(2):312-21.
Score: 0.073
-
Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001 Dec; 299(3):825-31.
Score: 0.050
-
Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996 Aug; 6(4):329-39.
Score: 0.034
-
Edeki TI, Goldstein JA, de Morais SM, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. Pharmacogenetics. 1996 Aug; 6(4):357-60.
Score: 0.034
-
de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995 Oct; 58(4):404-11.
Score: 0.032
-
Br?sen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995 Oct; 5(5):312-7.
Score: 0.032
-
Yeowell HN, McClellan-Green PD, Negishi M, Goldstein JA. Characterization of a cDNA for the unexpressed form of cytochrome P-450g from the (-g) rat and differentiation of its mRNA from that of the (+g) phenotype using specific oligoprobes. Biochemistry. 1990 Jan 23; 29(3):713-8.
Score: 0.022
-
Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos. 1998 Mar; 26(3):278-83.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|